Published in Cancer Weekly, November 1st, 2005
According to recent research published in the journal Cancer, "because a role for nuclear factor-kappa B (NF-kappa B) has been implicated in the pathogenesis of pancreatic carcinoma, this transcription factor is a potential target for the treatment of this devastating disease. Curcumin (diferuloylmethane) is a phytochemical with potent NF-kappa B-inhibitory activity."
"It is pharmacologically safe, but its bioavailability is poor after oral administration. The authors encapsulated curcumin in a liposomal delivery system that would allow intravenous administration. They...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.